AUTHORS
Ashley L Lennox, PhD, Mario González-Sales, PhD2, Martin Johnson, PhD3, Qi Xia4, Libo Sun5, Michelle Mudge-Riley, DO6, Joseph Eid7
AFFILIATIONS
1 Geron Corporation, Foster City, California, United States
2 Modeling Great Solutions Pharmaceutical Research & Studies, FZE, Dubai, United Arab Emirates
3 Allucent, Cary, North Carolina, United States
4 Geron Corporation, Foster City, California, United States
5 Geron Corporation, Foster City, California, United States
6 Geron Corporation, Foster City, California, United States
7 Geron Corporation, Foster City, California, United States
ABSTRACT
Introduction: Imetelstat, a first-in-class telomerase inhibitor, was approved in the United States and Europe for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with red blood cell (RBC) transfusion–dependent anemia who are relapsed or refractory to, or ineligible for, erythropoiesis-stimulating agents based on the IMerge Phase 3 study (NCT02598661; Platzbecker U and Santini V, et al. Lancet. 2024). In IMerge, patients received 7.1 mg/kg imetelstat active dose (7.5 mg/kg imetelstat sodium equivalent) intravenously once every 4 weeks (q4w) or placebo. Imetelstat demonstrated superiority in achieving ≥8-week RBC transfusion independence. The most common grade 3/4 adverse events were neutropenia and thrombocytopenia. Here, we developed population pharmacokinetic (PK)/pharmacodynamic (PD) models to characterize the relationships between imetelstat exposures and clinically relevant hematologic parameters (hemoglobin [Hb], platelet count, and neutrophil count) related to efficacy and safety, and evaluated alternative imetelstat dosing regimens, including fractionated and reduced intensity regimens.
Methods: Data from imetelstat-treated, population PK/PD–evaluable patients pooled across IMerge Phase 2, Phase 3, and QTc substudy were used, including PK concentrations, time course of hematology laboratory values, dosing history, baseline patient characteristics, and interventions known to significantly impact laboratory measures (eg, transfusions). The final analysis (data cutoff date: October 13, 2023) was used. Three semimechanistic PK/PD models adapted from a published framework (Friberg LE, et al. J Clin Oncol. 2002) were developed to quantify imetelstat effects on neutrophil count, platelet count, and Hb dynamics using nonlinear mixed-effects modeling. Simulations assessed the impact of alternative imetelstat dosing regimens on the incidence of safety-related outcomes (grade 3/4 neutropenia and grade 3/4 thrombocytopenia) and efficacy outcomes (Hb response; mean ≥1.5-g/dL rise in Hb sustained ≥12 weeks).
Results: A total of 206 patients were included in this analysis as follows: 61.7% were male, median age was 71.0 years, 66% and 34% had low- and intermediate-risk disease per the International Prognostic Scoring System, respectively, and median baseline RBC transfusion burden was 6.0 units per 8 weeks. Imetelstat PK was described by a 2-compartment model with linear elimination and body weight allometry. Each PK/PD model comprised a proliferating progenitor compartment, a series of transit compartments to capture maturation delays, and a circulating compartment, and included homeostatic feedback on proliferation. Drug effects were modeled via linear inhibition of progenitor proliferation for neutrophils and platelets, and stimulation of Hb. All models demonstrated robust performance and predictive accuracy confirmed through parameter precision, goodness-of-fit diagnostic plots, and predictive checks versus observed study data. Simulations predicted that imetelstat 7.1 mg/kg q4w would achieve robust efficacy and acceptable safety. Fractionated dosing regimens (5.6 mg/kg once every 3 weeks and 3.55 mg/kg once every 2 weeks) are predicted to produce minimal relative changes (<5%) in rates of grade 3/4 cytopenias or Hb response versus the approved dosing regimen. Reduced-intensity regimens (5.6 mg/kg q4w, 4.4 mg/kg q4w, and 3.55 mg/kg q4w) are predicted to result in dose-dependent and parallel reductions in both grade 3/4 cytopenias and Hb response.
Conclusions: Alternative imetelstat regimens, including sustained dose reductions or modified schedules, are unlikely to simultaneously reduce grade 3/4 cytopenias while preserving efficacy, thereby reducing potential clinical benefit. These data are consistent with the on-target nature of cytopenias and support the approved 7.1-mg/kg q4w dosing regimen for LR-MDS and adherence to cytopenia management guidance in the prescribing information.
DISCLOSURES
Ashley L Lennox, PhD: Geron - Current equity holder in publicly-traded company; Geron - Current Employment